Cargando…

AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure

Previous studies have underlined the substantial role of nuclear factor of activated T cells (NFAT) in hypertension-induced myocardial hypertrophy ultimately leading to heart failure. Here, we aimed at neutralizing four members of the NFAT family of transcription factors as a therapeutic strategy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Remes, Anca, Wagner, Andreas H., Schmiedel, Nesrin, Heckmann, Markus, Ruf, Theresa, Ding, Lin, Jungmann, Andreas, Senger, Frauke, Katus, Hugo A., Ullrich, Nina D., Frey, Norbert, Hecker, Markus, Müller, Oliver J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178147/
https://www.ncbi.nlm.nih.gov/pubmed/34089101
http://dx.doi.org/10.1007/s00395-021-00880-w
Descripción
Sumario:Previous studies have underlined the substantial role of nuclear factor of activated T cells (NFAT) in hypertension-induced myocardial hypertrophy ultimately leading to heart failure. Here, we aimed at neutralizing four members of the NFAT family of transcription factors as a therapeutic strategy for myocardial hypertrophy transiting to heart failure through AAV-mediated cardiac expression of a RNA-based decoy oligonucleotide (dON) targeting NFATc1-c4. AAV-mediated dON expression markedly decreased endothelin-1 induced cardiomyocyte hypertrophy in vitro and resulted in efficient expression of these dONs in the heart of adult mice as evidenced by fluorescent in situ hybridization. Cardiomyocyte-specific dON expression both before and after induction of transverse aortic constriction protected mice from development of cardiac hypertrophy, cardiac remodeling, and heart failure. Singular systemic administration of AAVs enabling a cell-specific expression of dONs for selective neutralization of a given transcription factor may thus represent a novel and powerful therapeutic approach. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-021-00880-w.